RxDoctor Payments Data

Fallon Houk

Family · Canton, GANPI 1417628728

Payments from drug & device makers

$1,905in general payments, 2019–2025

Across 77 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$559
  • AstraZeneca$353
  • Novo Nordisk$281
  • Sanofi-aventis U.S. LLC$245
  • Astellas Pharma US Inc$161
  • Sumitomo Pharma America, Inc.$75
  • plus $230 from 9 others

What the payments were for

  • Food & beverage$1,905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,905 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$57,180
Medicare patients
229
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$80,045
EliquisApixaban58$53,147
MounjaroTirzepatide29$30,069
JanuviaSitagliptin Phosphate16$13,369
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$13,053
TradjentaLinagliptin13$12,903
JardianceEmpagliflozin11$10,697
Breo ElliptaFluticasone/Vilanterol25$9,849
XareltoRivaroxaban13$9,528
Victoza 2-PakLiraglutide11$5,837
Levothyroxine Sodium520$5,223
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,685
Doxycycline Hyclate15$3,519
SynthroidLevothyroxine Sodium69$3,149
Varenicline Tartrate14$3,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$281$80,04567 claims
PfizerEliquis$30$53,14758 claims
Lilly USA, LLCMounjaro$15$30,06929 claims
GSKBreo Ellipta$20$9,84925 claims
AbbVieSynthroid$559$3,14969 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →